Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study

समान संसाधन

• Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
  द्वारा: Mysler, E, और अन्य
  प्रकाशित: (2022)
• Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
  द्वारा: Roy Fleischmann, और अन्य
  प्रकाशित: (2024-03-01)
• Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
  द्वारा: Taylor, P, और अन्य
  प्रकाशित: (2019)
• Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
  द्वारा: Roy Fleischmann, और अन्य
  प्रकाशित: (2024-05-01)
• Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
  द्वारा: Thomas Huizinga, और अन्य
  प्रकाशित: (2023-02-01)